Abstract
Despite being a rare disease, high-income countries (HICs) have formulated guidelines for management of pediatric CML (pCML). We conducted a survey amongst 24 physicians from 22 Low-Middle Income Countries (LMICs) to gather information regarding their practice and experience in treating children with pCML. Rarity of pCML, lack of adequate expertise, and setting-adapted guidelines along with limitations in diagnostic infrastructure as well as challenges in accessing tyrosine kinase inhibitors (TKIs) were identified as major barriers in optimum management of patients. For the first time in literature, our findings provide valuable insights into the multifaceted challenges faced in managing pCML in LMICs.
Acknowledgements
Diana Altuna (Argentina), Sabina Karim (Bangladesh), Israel Bendit (Brazil), Qian Jiang (China), Isabel Cristina Sarmiento Urbina (Columbia), Abdulkadir Mohamed Said Gidey (Ethiopia), Miri Turkana (Fiji), Banbeng Adrianto (Indonesia), Nur Melani Sari (Indonesia), Irene Nzamu(Kenya), George Chagaluka (Malawi), Norma Lopez-Santiago (Santiago), Sucharita Tuladhar (Nepal), Gregory Harvet (New Caledonia), Lateef Salawu (Nigeria), Adefehinti Olufemi (Nigeria), Salam Al-Kindi (Oman), Zeba Aziz (Pakistan), Gwenda Anga (Papua New Guinea), Mohamed Yassin (Qatar), Eli Mkwizu (Tanzania), Milenalay Santos (Timor l‘Este), and George Aho (Tonga) for completing the survey.
Disclosure statement
No potential conflict of interest was reported by the author(s).